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Objectives: To determine whether immediate (less than 3 months from time of nerve injury), early (from 3 to 6
months from time of nerve injury) or late (more than 6 months from time of nerve injury) vocal fold injection
influences the long-term outcomes for patients with permanent unilateral vocal fold paralysis.
Methods: A total of 250 patients with documented unilateral vocal fold paralysis were identified in this
retrospective chart review. 66 patients met the inclusion criteria, having undergone awake trancervical injection
with gelfoam™, collagen, perlane™ or a combination. Patients with documented recovery of vocal fold mobility, or
patients with less than one year of follow-up after the onset of paralysis were excluded. Patients were stratified into
immediate (<3 months), early (3-6 months) and late (>6 months) groups denoting the time from suspected injury
to injection. The need for open surgery as determined by a persistently immobile vocal fold with insufficient glottic
closure following injection was the primary outcome.
Results: 1 out of 21 (4.8%) in the immediate group, 2 out of 17 (11.8%) in the early group and 20 out of 28 (71.4%)
in the late group required type 1 thyroplasty procedures to restore glottic competence. There was significance
when comparing late injection to both early and immediate injection (p < 0.001). No statistically significant
differences were seen when comparing the number of injections needed to restore glottic competence.
Conclusions: This 10-year longitudinal assessment revealed that early medialization of a permanent paralyzed,
abducted vocal fold with a temporary material appears to diminish the likelihood of requiring permanent laryngeal
framework surgery.Introduction
Vocal fold immobility is a broad term used to describe
vocal folds that are restricted secondary to mechanical
fixation or neuropathy. Mechanical fixation may result
from an arytenoid dislocation, edema or inflammation of
the glottis, or neoplastic invasion. Neurogenic immobil-
ity may occur with lesions in the motor cortex or com-
promise of the recurrent laryngeal nerve due to either
surgical iatrogenic injury or extra-laryngeal malignancies
at any point along its course from the jugular foramen
to the carotid sheath, mediastinum, and either around
the subclavian artery on the right or the aortic arch on
the left, to the tracheoesophageal groove [1]. The
resulting glottic insufficiency may lead to dysphonia,* Correspondence: Yazeed.alghonaim@gmail.com
Department of Otolaryngology – Head & Neck Surgery, McGill University, 687
Pine Ave. West, Montreal, QC H3A 1A1, Canada
© 2013 Alghonaim et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumaspiration, and shortness of breath. Iatrogenic stretching
or transection of the recurrent laryngeal nerve may
cause only temporary immobility. However, if there is no
recovery, procedures aiming to restore glottic compe-
tence include permanent and temporary vocal fold injec-
tions (VFI) or laryngeal framework surgery, such as type
1 thyroplasty.
Different injection materials, either permanent (Teflon,
PDMS) or temporary (Gelofoam, Cymetra, Restylane,
Radiesse) and different approaches (transoral vs. percutan-
eous) have been used to medialize the paretic vocal fold in
order to improve voice and prevent aspiration [2]. Previ-
ous approaches to unilateral vocal fold paralysis included
waiting several months for spontaneous recovery to be
ruled out before proceeding with medialization [3]. Recent
evidence, however, suggests that early intervention re-
duces the need for transcervical reconstruction [4].tral Ltd. This is an Open Access article distributed under the terms of the
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to eventual need for type 1 thyroplasty. In this retrospect-
ive chart review, we study the different parameters avail-
able to laryngologists for VFI. Specifically, we compare
immediate, early and late (>3 months, 3-6 months and >6 -
months, respectively) injection when using different
materials.
Materials and methods
The study was approved by The Research Ethics Board
(REB) of McGill University Health Center (MUHC). A
retrospective chart review between Jan 2000 and Sept
2011 identified all adult patients initially presenting at
our Voice center and diagnosed during laryngoscopy
with UVFP. Of the 250 patients with unilateral vocal fold
paralysis, 66 met the inclusion criteria of having under-
gone injection medialization as initial treatment within
1 year of onset of their paralysis, and these formed the
study group.
Patients were stratified into immediate (<3 months),
early (3-6 months) and late (>6 months) groups denoting
the time from suspected injury/onset of dysphonia to in-
jection. All patients in the study had one or more injec-
tions. Hyaluronic acid (perlane™) absorbable gelatin
(Gelfoam™) or collagen were injected using a trans-
cricothyroid technique. Three senior laryngologists
performed the injections on these patients in the same
voice lab – all following the same technique. They all
injected within each of the immediate, early and late
groups. At the time of data collection, 21 patients had
injection in <3 months, 17 patients between 3-6 months
and 28 had their injections after 6 months. 51 patients
had an identifiable cause of paralysis (iatrogenic, malig-
nancy or stab injury), 15 were considered as idiopathic
which was confirmed by routine work-up which may have
included CT, MRI, barium swallow, thyroid ultrasound,
flexible endoscopy and autoimmune workup. Glottic com-
petency was determined based on the patients’ subjective
voice quality as well as objectively using the laryngoscope.
Results
Of the 250 patients with unilateral vocal fold paralysis col-
lected, 66 met the inclusion criteria (31 female, 35 male).
The average age of the cohort was 59.5 (range 23 – 84)
with no significant differences between the immediate,
early and late injection groups. All injections were
performed percutaneously in the office setting with local
anesthesia and most commonly utilized perlane™ (67%).
The descriptive statistics detailing cause of vocal fold
paralysis, length of follow-up, timing of injection and
outcome (open thyroplasty performed or avoided) are
included in Table 1.
In total, 29/66 of patients had UVFP secondary to an
oncologic etiology with 93% (27/29) a result of lungcancer. 30.3% (20/66) of patients had UVFP from iatro-
genic etiologies: 17 post-surgical and 3 from chemother-
apy or radiation therapy. The rest of the cohort suffered
glottic incompetence from trauma [2] and 15 from idio-
pathic processes (Figures 1 and 2).
21 patients were stratified into the immediate group
(<3 months), 17 patients to the early group (3-6 months)
and 28 patients to the late group (>6 months) denoting
the time from suspected injury to injection. A mean
delay of 42 days for the immediate group, 4.2 months
for the early group and 12 months for the late group
was observed. The average length of follow up from the
onset of dysphonia was 18 and 19 months for immediate
(range 12-48 mothns) and early groups (range 12-
36 months) respectively and 32.7 months (range 12-
74 months) for late group. 62 patients had left and four
had right UVFP.
Many of the patients in this study required more than
one injection to achieve glottic competency and a satis-
factory voice. Thirty-nine (59.1%) required at least two
and fifteen (22.7%) required at least three. Two patients
required more than 3 injections. Eight patients achieved
glottic competency with only one injection from the im-
mediate group compared to six from the early group.
Ultimately twenty-three of 66 patients failed to achieve
glottic competency and required laryngeal framework
surgery and forty-three had documented medialization
of the paralyzed vocal fold with a noted improvement in
objective and subjective voice quality. Of the twenty-
three patients who required laryngeal framework sur-
gery, one was from the immediate group (1/21, 4.8%),
two from the early group (2/17, 11.8%) and twenty from
the late group (20/28, 71.4%).
Patients who received injections during the immediate
3-month window were 66.7% (95% CI = 47.6 – 85.7) less
likely to undergo surgery than those injected after 6 -
months (P <. 001). Patients who received injections during
the early 3 to 6 month window were 59.7% (95% CI = 37 –
82.3) less likely to undergo surgery than those injected
after 6 months (P <. 001). Only a 7% difference is seen
when comparing the immediate vs. early groups (-10.8 –
24.8) (P >. 05).
Discussion
The rationale for medializing a paralyzed true vocal fold is
to restore glottic competence in order to improve voice
quality and prevent aspiration. The optimal time and
method of vocal fold paralysis management is controver-
sial. Factors contributing to the controversy include un-
certainty regarding the possible return of function, and
concern about the irreversibility of some procedures [5].
Initial treatment options for UVFP include temporary
vocal fold injection medialization, voice therapy, or obser-
vation for spontaneous return of function.
Table 1 Unilateral vocal fold paralysis patient cohort characteristics
Age Gender Etiology Length of follow-up months Number of injections Time of thyroplasty type-I
Immediate group (n = 21)
46 F Thyroidectomy 48 1 No
53 F Idiopathic 48 3 No
43 F Parathyroidectomy 14 2 No
74 M Neck Ca (chemo/XRT) 30 3 No
66 M Lung Ca 12 1 No
25 M Neck stab injury 24 2 No
41 F Throidectomy 16 1 No
23 M Gunshot to C1 19 3 No
72 M Lung Ca 13 2 Yes (13)
53 F Thyroidectomy 12 3 No
72 M Lung Ca 12 1 No
82 M Lung Ca 12 2 No
66 M Lung Ca 14 2 No
49 F Thyroidectomy 17 2 No
50 F Breast Ca 12 1 No
75 M Lung Ca 12 1 No
39 M Thyroidectomy 12 1 No
66 M Lung Ca 14 3 No
70 M Lung Ca 12 1 No
66 M Mediastenoscopy 16 3 No
70 M Lung Ca 12 2 No
Early group (n = 17)
66 M Lung Ca 12 1 No
77 M Idiopathic 12 2 Yes (12)
48 F Thyroidectomy + XRT 24 2 No
70 F Lung Ca 12 1 No
62 F Lung Ca 12 1 No
63 F Lung Ca 24 2 No
66 F Aortic Surgery 12 2 No
68 M Lung Ca 30 2 No
59 M Idiopathic 12 1 No
65 M Lung Ca 16 2 No
46 F Mediastenscopy 14 1 Yes (10)
80 M Idiopathic 20 2 No
60 M Lung Ca 14 2 No
84 F Idiopathic 36 2 No
78 M Mediastinal Ca 12 1 No
70 F Lung Ca 14 2 No
40 F NP Ca/XRT 30 2 No
Late group (n = 28)
70 F NP Ca (XRT) 36 1 Yes (13)
58 F Thyroidectomy 60 3 No
84 F Lung Ca 14 1 No
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Table 1 Unilateral vocal fold paralysis patient cohort characteristics (Continued)
72 F Lung Ca 14 1 Yes (8)
59 M Lung Ca 24 1 Yes (14)
64 M Carotid Surgery 16 1 Yes (20)
67 F Idiopathic 20 2 Yes (22)
36 F Idiopathic 60 3 Yes (40)
61 M Idiopathic 60 3 Yes (26)
40 F Schwanoma skull base 50 3 Yes (38)
68 M Lung Ca 36 1 Yes (20)
49 F Idiopathic 72 7 Yes (50)
71 F Lung Ca 16 1 No
30 F Idiopathic 36 2 Yes (30)
60 F Aortic surgery 20 2 Yes (18)
62 M Aortic surgery 30 1 Yes (25)
70 M Idiopathic 48 2 Yes (24)
61 F Lung Ca 13 1 Yes (12)
60 M Lung Ca 24 1 Yes (16)
47 M Idiopathic 36 1 Yes (12)
50 M Palatectomy/maxillectomy 16 2 Yes (16)
56 M Idiopathic 32 3 No
42 F Idiopathic 21 2 Yes (15)
65 F Lung Ca 14 1 No
49 M Lung Ca 74 2 Yes (74)
62 M Lung Ca 28 2 No
40 F Thyroidectomy 20 1 No
71 M Idiopathic 25 3 No
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of laryngoplasty with the introduction of a temporary
injectable collagen to restore the glottic competence
[6]. Since then, several materials for injections have
been developed and are typically described as either
temporary, long lasting or permanent. Long lasting/per-
manent injectable materials include autologous fat,Figure 1 Etiology of unilateral vocal fold immobility.calcium hydroxylapatite (Radiesse™), polydimethylsiloxane
(PDMS or particulate silicone), and historically, polytef
paste (Teflon™) [2]. Temporary injection materials include
bovine gelatin (Gelfoam™, Surgifoam™), collagen-based
products (Cymetra™, Zyplast™, Cosmoplast/Cosmoderm™),
hyaluronic acid (Restylane™, Perlane™, Hyalaform™), and
carboxymethylcellulose (Radiesse Voice Gel™) [2].
Figure 2 Comparison of need for type-1 thyroplasty at Immediate (<3 months), early (3-6 months) versus late (>6 months) groups.
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an essential element of appropriate workup and treat-
ment. Rosenthal and colleagues [1] found that the most
common etiology for unilateral immobility is secondary
to surgical iatrogenic injury (thyroid and non-thyroid).
Aside from surgery, other common causes of vocal fold
paralysis include extralaryngeal malignancy, idiopathic
causes and trauma. In our cohort, the majority of the
patients 43.9% (29/66) had UVFP secondary to a malig-
nant etiology followed by 30.3% (20/66) of patients who
had UVFP from iatrogenic etiologies. This distribution
might be explained by the referral pattern in our institu-
tion and the fact that most of the post thyroidectomy
patients were excluded from our sample because they
regained their nerve function. The left recurrent laryn-
geal nerve (94%) was more commonly injured in our
study than the right (6%). This is consistent with the
prior literatures and can be explained by its longer and
more convoluted course.
Previously, it was accepted that waiting several months
before intervention would allow time for spontaneous re-
covery to occur. However, due to its ease of use and low
risk and complication rate, early injection laryngoplasty
under topical anesthetic provides an excellent therapeutic
option for both patients and physician. Awake injection
laryngoplasty produces a substantial improvement in voice
quality as measured by the Voice-Related Quality of-Life
(VRQOL) measure [7]. Moreover, injection laryngoplasty
produced improvements in Glottal Function Index (GFI),
GRBAS, Functional outcome swallowing scale (FOSS),
and maximum phonation time measurements, which con-
firm the advantage of this technique in improving glottic
competency [5]. Bhattacharyya et al. compared early andlate vocal fold medialization for vocal fold paralysis follow-
ing thoracic procedures and found a significantly reduced
risk of post-injection pneumonia and length of hospital
stay for the early injected group [8]. Friedman et al. re-
cently hypothesized that with early intervention (less than
6 months from time of injury), the implant material allows
the vocal fold to be in a more appropriate resting position
during the time window of synkinetic reinnervation. It is
possible that synkinetic reinnervation permanently main-
tains a medialized and more favorably positioned vocal
fold. Conversely, a non-injected vocal fold which has been
assumed a more lateralized (and less favorable) position
following synkinetic reinnervation is less likely to be ad-
equately adducted with injection [4]. In fact, there might
be a greater degree of benefit to an even earlier acute
intervention (i.e., sooner than six months after paralysis)
in terms of decreasing the likelihood of requiring a subse-
quent permanent laryngeal framework procedure [9].
In our study, which defined immediate intervention to
be less than three months post paralysis, the percentage
of patients requiring open surgery following injections
because of inadequate long-term results was 4.8%, which
is even lower than (37.5%) what was found by Friedman
et al. Only a 7% difference (not statistically significant) is
seen when comparing the immediate vs. early groups
(-10.8 – 24.8). However, patients who received injections
during the immediate or early window were 66.7% and
59.7% (95% CI = 47.6 – 85.7) and (95% CI = 37.0 – 82.3)
respectively less likely to undergo surgery than those
injected after 6 months (late group). It is a common
misconception that vocal fold paralysis is the result of
complete muscle denervation. Animal experiments dem-
onstrate that synkinetic reinnervation occurs in more
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comparable to that in humans [10-12].
Many of the patients in this study required more than
one injection due to ongoing dysphonia or glottic in-
competency. Thirty-nine (59.1%) required at least two
injections, including 13 from the immediate, 11 from the
early, and 15 from the late groups. Owing to low sample
sizes within each group, comparisons between groups
are inconclusive. When speaking of recovery, several au-
thors have described return of function in general terms,
noting that “all cases recovered in less than twelve
months”. However, many documented no further recov-
ery after much shorter intervals [13]. Although delayed
recovery as long as 4 years following onset has been very
occasionally been noted [14], allowing a one year inter-
val before assuming the paralysis to be permanent and
instituting final treatment would seem reasonable. In
our sample, all patients who were lost to follow up in
less than one year were excluded. The average of follow
up from the onset of dysphonia was 18 and 19 months
for immediate and early groups respectively, 32.7 months
for late group. Finally, patient age has long been recog-
nized as an essential factor in motor nerve regeneration,
and many studies have confirmed this finding [15].
Response to the injection and/or thyroplasty was not
significantly affected by age in our study.
Our current study has a number of methodologic limi-
tations. First, poor intra-operative documentations of
nerve transecting/injury or not, could affect prediction
of the final outcome. Second, the data were collected
retrospectively on a small sample size and with no EMG
study and Speech Language Pathology assessment.
Finally, a selection bias exists. Most patients seeking
medical therapy after greater than six months of glottic
incompetence may have been more likely to accept the
need for surgical intervention, compared to the patients
that were motivated to undergo early intervention in the
form of injection in the office.
Conclusions
This 10-year longitudinal assessment revealed that
patients who received a temporary vocal fold injec-
tion for a newly diagnosed vocal fold immobility (less
than 6 months) were less likely to undergo permanent
medialization laryngoplasty (thyroplasty) compared with
those patients who were treated with conservative
management alone or had delayed treatment after 6 -
months. Further studies with a speech language path-
ology assessment, EMG study and a longer lasting
injectables such as radiesse™ for vocal fold paralysis
are warranted.
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